Physician profile
Robert B Canada
NPI 1033176250
$20,225.96
in general payments reported to CMS, 2019-2025
37 companies · $3,592 in 2025
The $3,592 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,261 · 2020: $3,372 · 2021: $1,626 · 2022: $1,165 · 2023: $1,625 · 2024: $1,585 · 2025: $3,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,950 · Travel and Lodging: $579 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,949.58 |
| Travel and Lodging | $578.76 |
| Education | $274.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,674.66 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $1,056.16 | 2021-2025 | |
| Vantive US Healthcare LLC | $929.31 | 2025 | Renal - Acute |
| Gilead Sciences, INC. | $763.03 | 2019-2025 | Descovy, Biktarvy |
| Fresenius USA Marketing, INC. | $758.54 | 2019-2025 | Velphoro, Velphoro |
| Nxstage Medical, INC. | $755.77 | 2021-2025 | Nxstage System One, Liberty Select Cycler, Pureflow Sl |
| Otsuka America Pharmaceutical, INC. | $719.54 | 2019-2025 | Jynarque, Voyxact |
| Aurinia Pharma U.S., INC. | $686.99 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $661.50 | 2022-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $644.86 | 2020-2025 | Acthar, Terlivaz |
| Ardelyx, INC. | $482.63 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Amgen INC. | $413.38 | 2019-2025 | Tavneos |
| Genzyme Corporation | $266.04 | 2024-2025 | |
| Viiv Healthcare Company | $265.72 | 2021-2025 | Dovato, Rukobia |
| Ani Pharmaceuticals, INC. | $245.99 | 2022-2025 | Purified Cortrophin Gel |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Canada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.